emerging glp-1 gip treatments 2025 research on metabolic therapies in 2025–2026 show major advances with newer drugs targeting multiple metabolic pathways. , Triple-receptor agonists like retatrutide, which act on GLP-1, GIP, The first of three of

The number of cases grew from 1,221 in November to 1,300 in December, with 79 new claims filed

Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists

It can even help you flag and treat any unwanted side effects earlier rather than later

doi: 10.3389/fmolb.2025.1622186 Leri M, Bertolini A, Diaz M and Marongiu R (2025) Editorial: Estrogens and neurodegeneration: a link between menopause and Alzheimers disease in women